Novavax, Inc. (NVAX) concluded trading on Wednesday at a closing price of $3.89, with 3.71 million shares of worth about $14.43 million changed hands on the day. Half year performance of the stock remained negative as price took a plunge of -41.33% during that period and on April 17, 2024 the price saw a loss of about -2.51%. Currently the company’s common shares owned by public are about 139.51M shares, out of which, 133.04M shares are available for trading.
Stock saw a price change of -8.69% in past 5 days and over the past one month there was a price change of -24.32%. Year-to-date (YTD), NVAX shares are showing a performance of -18.96% which decreased to -58.88% when we look at its performance for past 12 months. Over the period of past 52 weeks, stock dropped to lowest price of $3.53 but also hit the highest price of $11.36 during that period. The average intraday trading volume for Novavax, Inc. shares is 7.51 million. The stock is currently trading -14.24% below its 20-day simple moving average (SMA20), while that difference is down -16.79% for SMA50 and it goes to -36.84% lower than SMA200.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Novavax, Inc. (NASDAQ: NVAX) currently have 139.51M outstanding shares and institutions hold larger chunk of about 56.87% of that.
The stock has a current market capitalization of $544.41M and its 3Y-monthly beta is at 1.64. It has posted earnings per share of -$5.54 in the same period. It has Quick Ratio of 0.67. Volatility of a stock is a metric used to know how much the price of that stock is under influence and for NVAX, volatility over the week remained 5.02% while standing at 5.06% over the month.
Stock’s fiscal year EPS is expected to rise by 86.44% while it is estimated to increase by 92.73% in next year.
Digging deeper we find that several firms have released their research notes about the support levels of the stock. Most recent of them is a note released by B. Riley Securities on August 09, 2023 offering a Buy rating for the stock and assigned a target price of $15 to it. Coverage by TD Cowen stated Novavax, Inc. (NVAX) stock as a Market perform in their note to investors on April 20, 2023, suggesting a price target of $10 for the stock. On March 01, 2023, B. Riley Securities Downgrade their recommendations, while on January 09, 2023, B. Riley Securities Reiterated their ratings for the stock with a price target of $37. Stock get a Buy rating from H.C. Wainwright on December 30, 2022.
